Citations

Clear

1281 citation(s) found for "Hong, Na".

Consensus Statements—Optimizing Performance of the Elite Athlete
Bangsbo, Jens , Hostrup, Morten , Hellsten, Ylva , Hansen, Mette Halskov, Egan, Brendan , Hackney, Anthony C. , Chambers, Toby L. , Deshmukh, Atul S. , Elliott‐Sale, Kirsty J. , Joyner, M. J., Christensen, Peter M. , Kissow, Julie , Jeppesen, Jan S. , Moesgaard, Lukas , Egan, Brendan , Hackney, Anthony C , Magnusson, Peter , Calbet, Jose A L , Elliott-Sale, Kirsty , Joyner, Mike, Christensen, Peter M , Joyner, Michael J , Rømer, Tue , Wickham, Kate A , Jessen, Søren K , Jeppesen, Jan S , Moesgaard, Lukas , Hellsten, Ylva , Hansen, Mette, Melin, Anna , Kjær, Michael , Burr, Jamie F. , Engebretsen, Lars , Jones, Andrew M. , Pitsiladis, Yannis , Petersen, Jesper, Calbet, José A. L. , Andersen, Jesper L.

Mayo Clinic

Scandinavian Journal of Medicine & Science in Sports | August 9, 2025 | Volume: 35 | Issue: 8 | Pages: No page available

10.1111/sms.70112 | PMID 40781883 Get It

ABSTRACT The International Consensus Conference “Optimising Performance of the Elite Athlete,” held in November 2024, brought together 29 scientists, some coaches, and athletes to establish evidence‐based consensus statements aimed at enhancing elite athletic performance and health. The conference addressed critical themes including training strategies, nutrition, female athlete considerations, injury management, and emerging technologies. Key conclusions emphasize individualized, sport‐specific approaches to training and nutrition, integrating concurrent training modalities to improve endurance, resilience, and efficiency. Nutrition strategies highlight the importance of tailored energy and macronutrient periodization, recognition of low energy availability risks, and cautious use of dietary supplements. Special attention was directed to female athletes, advocating for improved monitoring of menstrual cycles and hormonal status, while acknowledging current knowledge gaps in hormonal influences on performance and injury risk. Injury prevention remains a challenge, with tendon overuse and Achilles tendon ruptures significantly impacting athlete careers; rehabilitation should rely on criteria‐based progression and multidisciplinary input. Emerging technologies, including wearable sensors and multi‐omics analyses, hold promise for personalized training and nutrition but require further validation in elite contexts. Despite robust consensus, the panel identified substantial research gaps, particularly regarding female athletes, longitudinal training effects, and efficacy of novel interventions. This consensus provides a practical, scientifically grounded framework to optimize elite athlete performance and health, while underscoring the need for continued research to address outstanding questions and promote inclusive evidence‐based practices.
Exercise and Atrial Fibrillation: Current Evidence, Knowledge Gaps, and Future Directions
Pham, Hoang Nhat , Abdelnabi, Mahmoud , Ibrahim, Ramzi, Sainbayar, Enkhtsogt , Truong, Hong Hieu, Habib, Eiad , Bcharah, George , Sorajja, Dan , Abdelnabi, Mahmoud , Pathangey, Girish , Chahal, Anwar A, Nhat, Hoang , Ibrahim, Ramzi, Singh, Amitoj , Arsanjani, Reza , Chahal, C. Anwar A.

Mayo Clinic

Reviews in Cardiovascular Medicine | August 6, 2025 | Volume: 26 | Issue: 7 | Pages: No page available

10.31083/rcm39200 | PMID 40776961 Get It

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, contributing to significant morbidity and mortality worldwide. The relationship between physical exercise and AF is complex, with studies showing both beneficial and potentially adverse effects. Moreover, evidence suggests a U-shaped association between exercise intensity and AF risk. Moderate exercise has been shown to reduce AF burden by improving cardiovascular risk factors, enhancing autonomic regulation, and mitigating atrial fibrosis. In contrast, excessively high-intensity endurance exercise may increase AF risk, particularly in young athletes, due to atrial stretching, dilation, fibrosis, autonomic imbalances, and heightened inflammation. The current guidelines emphasize exercise as a core lifestyle intervention for AF management, recommending moderate-intensity aerobic activity for optimal outcomes. This review examines the current evidence on the effects of exercise on AF, identifies knowledge gaps, and proposes potential future research directions.
CD19 Directed CAR T Therapy for Transformed Follicular Lymphoma: A CIBMTR Analysis
Kambhampati, Swetha , Ahn, Kwang Woo , Patel, Jinalben , Lian, Qinghua, Hertzberg, Mark P. , Metheny, Leland , Hong, Sanghee , Jain, Tania , Aljurf, Mahmoud, Vaughn, John L. , Wirk, Baldeep , Manjappa, Shivaprasad , Oliver, Carolina , Mohty, Razan , Hamadani, Mehdi, Herrera, Alex F. , Thiruvengadam, Swetha Kambhampati , Epperla, Narendranath , Jain, Tania , Iqbal, Madiha , Wirk, Baldeep , Oliver, Carolina , Shadman, Mazyar , Herrera, Alex F , Hertzberg, Mark, Epperla, Narendranath , Aljurf, Mahmoud , Beitinjaneh, Amer , Gopal, Ajay K. , Iqbal, Madiha , Shadman, Mazyar , Turtle, Cameron J. , Hamadani, Mehdi

Mayo Clinic

American Journal of Hematology | August 5, 2025 | Volume: 100 | Issue: 10 | Pages: 1803-1812

10.1002/ajh.70027 | PMID 40762207 Get It

ABSTRACT Transformed follicular lymphoma (tFL) is typically associated with chemotherapy resistance and a poor prognosis. There are limited data regarding outcomes after CD19‐directed chimeric antigen receptor T‐cell (CAR T) therapy in relapsed/refractory (R/R) tFL. A total of 923 adult patients with R/R tFL who received commercial CD19 CAR T therapy between 2017 and 2023 were identified in the Center for International Blood and Marrow Transplant Research registry. Median age was 64 years (range: 30–86) and median prior lines of therapy was 4 (range: 1–18). Most patients (78%) received axicabtagene ciloleucel, with 67% of patients having resistant disease at the time of CAR T infusion. At a median follow‐up of 25 months (range: 1–72) from CAR T infusion, the 2‐year overall survival (OS) was 57% (95% CI: 53–60) and progression‐free survival (PFS) was 43% (95% CI: 40–47). The 2‐year cumulative incidences of relapse or progression (rel/prog) and non‐relapse mortality (NRM) were 47% (95% CI: 44–51) and 9% (95% CI: 7–11), respectively. The overall response rate to CAR T was 76%, with a complete response rate of 63%. Grade ≥ 3 cytokine release syndrome (CRS) was observed in 7.1% and grade ≥ 3 immune effector cell–associated neurologic syndrome (ICANS) in 21.6% of patients. Multivariable analysis suggested that resistant disease status at the time of CAR T, use of bridging therapy, and high comorbidity index ≥ 3 were associated with inferior PFS and OS. Older age ≥ 60 significantly increased the risk of NRM. Our study suggests that CD19 CAR T is effective and safe for tFL.
Modernizing diagnosis of Alzheimer's disease: A review of global trends and Asia‐specific perspectives
Carrillo, Marı́a C., Chen, Christopher , Choi, Seong Hye , Fontana, Igor C. , Graff‐Radford, Jonathan, Heidebrink, Judith L. , Hu, Chaur‐Jong , Ihara, Ryoko , Ip, Fanny C.F., Fitri, Fasihah Irfani , Jack, Clifford R. , Yoon, Soo Jin , Jia, Jianping , Kandiah, Nagaendran, Kowa, Hisatomo , Joie, Renaud La , Noritake, Ryoji, Okonkwo, Ozioma C. , Raman, Rema , Shen, Yong , Simuni, Tanya, Snyder, Heather M. , Sriwannopas, Orapitchaya, Wang, Huali , Zhou, Jin , Sexton, Claire E. , Carrillo, María C. , Simuni, Tanya , Chen, Christopher , Mahinrad, Simin , Jack, Clifford R , La Joie, Renaud , Simuni, Tanya , Iwatsubo, Takeshi , Sperling, Reisa Anne , Algeciras‐Schimnich, Alicia , Arai, Hidenori , Barron, Anna M. , Benzinger, Tammie L.S. , Graff‐Radford, Jonathan , Grill, Joshua D. , Ikeuchi, Takeshi , Iwata, Atsushi , Kandiah, Nagaendran , Kim, SangYun , Niimi, Yoshiki , Palmqvist, Sebastian , Rafii, Michael S. , Stoeckel, Luke E. , Flier, Wiesje M. van der , Wilcock, Donna M. , Zetterberg, Henrik , Mahinrad, Simin

Mayo Clinic

Alzheimer's & Dementia | August 5, 2025 | Volume: 21 | Issue: 8 | Pages: No page available

10.1002/alz.70536 | PMID 40760693 Get It

Abstract The landscape of Alzheimer's disease (AD) and related dementias (ADRD) diagnosis is evolving rapidly, driven by advances in disease understanding, biomarker tools, and disease‐modifying therapies. Modern diagnostic approaches emphasize biological precision, early detection, and dynamic frameworks that adapt to treatment‐induced changes in disease biology. These frameworks enable opportunities for personalized interventions—encompassing pharmacological and non‐pharmacological strategies—and for enhanced clinical trial design. However, implementing these advancements globally is influenced by diverse cultural, infrastructural, and regulatory factors. The 2024 Alzheimer's Association International Conference Advancements: Modernizing Diagnosis, held in Japan, provided a unique platform to explore these global dynamics, particularly from an Asian perspective. This article highlights key discussions from the conference, exploring the role of biomarker‐based diagnostic frameworks in shaping the future of AD/ADRD research, diagnosis, and treatment. We highlight regional challenges and successes and emphasize ethical considerations and practical strategies needed to ensure equitable access to diagnostic and therapeutic innovations. Highlights Advances in biomarkers are reshaping Alzheimer's disease diagnosis and treatment. Modern diagnostic frameworks highlight biological precision, early detection, and dynamic frameworks. The 2024 Alzheimer's Association International Conference Advancements: Modernizing Diagnosis explored challenges and opportunities in global biomarker implementation. The conference explored geographic‐specific impacts, focusing on Asia.
Preventive effect of postoperative Goreisan administration on symptomatic recurrence of chronic subdural hematoma: a systematic review and meta-analysis
Hong, Sukwoo , Shinya, Yuki , Wang, Zhen , Shinya, Yuki , Wang, Zhen, Bendok, Bernard R. , Saito, Nobuhito

Mayo Clinic

Neurological Research | July 31, 2025 | Volume: 48 | Issue: 6 | Pages: 686-698

10.1080/01616412.2025.2540944 | PMID 40740071 Get It

Treatment Times and In-Hospital Mortality Among Patients with ST-Elevation Myocardial Infarction Throughout the Waves of the COVID-19 Pandemic: Lessons Learned
Zègre‐Hemsey, Jessica K. , Goyal, Abhinav , Poudel, Ram , Thomas, Kathie , Ali, Murtuza J., Best, Patricia J.M. , Bieniarz, Mark, Fonarow, Gregg C. , French, William J. , Henry, Timothy D. , Hong, Haoyun, Jollis, James G. , Redlener, Michael , Spier, Travis, Stone, Harper, Wahab, Feras, Wang, Lanjing , Jacobs, Alice K. , Granger, Christopher B.

Mayo Clinic

COVID | July 25, 2025 | Volume: 5 | Issue: 8 | Pages: 114

10.3390/covid5080114 Get It

Previous studies about the COVID-19 pandemic on STEMI patient outcomes have conflicting results. It remains unclear if this may be attributed to regional differences and/or differences during COVID-19 wave periods. Using the American Heart Association Get With The Guidelines–Coronary Artery Disease registry data, we evaluated (1) time metrics related to STEMI system goals and (2) regional variation in STEMI incidence and in-hospital mortality during pandemic wave time periods. The study included all patients 18–100 years old admitted with STEMI (n = 72,516) to 1 of 435 American Heart Association Get With The Guidelines–Coronary Artery Disease hospitals (1 October 2019–31 December 2021). Of these, 70.8% were male and 73.0% non-Hispanic White, with a median age of 63 (IQR 18) years. Compared to pre-pandemic time frames, patients with STEMI had a higher risk profile, delayed time to treatment, were treated with fibrinolytic therapy or primary PCI, and were transferred for primary PCI at similar rates, and had higher adjusted in-hospital mortality (during the second wave in the South and Midwest). Preservation of STEMI systems of care resulted in an overall lower in-hospital mortality rate than predicted, although opportunities exist to improve treatment delays. Regional differences in mortality rates require further study.
NRG Oncology Liver Proton SBRT and Hypofractionated Radiation Therapy: Current Treatment Technical Assessment and Practice Patterns
Kang, Minglei , Taylor, Paige A. , Shen, Jiajian , Saini, Jatinder, Hong, Theodore S. , Liu, Wei , Xiao, Ying , Simone, Charles B. , Lin, Liyong , Liu, Wei , Xiao, Ying , Simone, Charles B , Lin, Liyong , Taylor, Paige , Shen, Jiajian , Zhou, Jun , Higgins, Kristin Ann

Mayo Clinic

Cancers | July 17, 2025 | Volume: 17 | Issue: 14 | Pages: 2369

10.3390/cancers17142369 | PMID 40723252 Get It

Background/Objectives: Proton therapy delivers highly conformal doses to the target area without producing an exit dose, minimizing cumulative doses to healthy liver tissue. This study aims to evaluate current practices, challenges, and variations in the implementation of proton stereotactic body radiation therapy (SBRT) and hypofractionated therapy for liver malignancies, with the goal of providing a technical assessment to promote broader adoption and support future clinical trials. Methods and Materials: An extensive survey was conducted by NRG Oncology across North American proton treatment centers to assess the current practices of proton liver SBRT and hypofractionated therapy. The survey focused on key aspects, including patient selection, prescription and normal tissue constraints, simulation and motion management, treatment planning, quality assurance (QA), treatment delivery, and the use of image-guided radiation therapy (IGRT). Results: This survey captures the current practice patterns and status of proton SBRT and hypofractionated therapy in liver cancer treatment. Proton therapy is increasingly preferred for treating inoperable liver malignancies due to its ability to minimize healthy tissue exposure. However, the precision required for proton therapy presents challenges, particularly in managing uncertainties and target motion during high-dose fractions and short treatment courses. Survey findings revealed significant variability in clinical practices across centers, highlighting differences in motion management, dose fractionation schedules, and QA protocols. Conclusion: Proton SBRT and hypofractionated therapy offer significant potential for treating liver malignancies. A comprehensive approach involving precise patient selection, treatment planning, and QA is essential for ensuring safety and effectiveness. This survey provides valuable insights into current practices and challenges, offering a foundation for technical recommendations to optimize the use of proton therapy and guide future clinical trials.
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
Mahadevan, Uma , Seow, Cynthia H. , Chaparro, María, Flanagan, Emma , Julsgaard, Mette , Kane, Sunanda V. , Watermeyer, Gillian , Fisher, Susan G. , Anderson, Phil, Duricova, Dana, Dubinsky, Marla C. , Long, Millie, IBD, Global Consensus Group for Pregnancy and, Barnes, Edward L, Chaparro, María, Kane, Sunanda, Ng, Siew, Fisher, Susan, Dubinsky, Marla, Long, Millie, Huang, Vivian , Julsgaard, Mette , Barnes, Edward L. , Chaparro, María, Friedman, Sonia , Ng, Siew C. , Torres, Joana , Yamamoto-Furusho, Jesus , Robinson, Christopher James , Fisher, Susan, Gearry, Richard B. , IBD, Global Consensus Group for Pregnancy and, Barnes, Edward L, Chaparro, María, Ng, Siew, Dubinsky, Marla, Long, Millie

Mayo Clinic

Inflammatory Bowel Diseases | July 15, 2025 | Volume: 31 | Issue: 10 | Pages: 2615-2664

10.1093/ibd/izaf171 | PMID 40874613 Get It

Abstract Background & Aims Pregnancy can be a complex and risk-filled event for women with inflammatory bowel disease (IBD). High-quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes. Limited provider knowledge leads to highly varied practices in care affected by local dogma, available resources, individual interpretation of the literature, and fear of harming the fetus. The variations in guidelines by different societies and countries reflect this and lead to confusion for physicians and patients alike. The Global Consensus Consortium is a group of 39 IBD and content experts and 7 patient advocates from 6 continents who convened to review and assess current data and come to an agreement on best practices based on these data. Methods The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) process was used when sufficient published data were available and the RAND (Research and Development) process in those instances where expert opinion was needed to guide consistent practice. Recommendations were informed by the guiding principle that maternal health best supports infant health. Results The topics were divided into ten categories with 34 GRADE recommendations and 35 consensus statements. Conclusions Overall, the goal of the group was to provide data-driven and practical guidance to improve the care of women with IBD around the globe based on the best available research.
Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi -NT in Patients with Advanced Solid Tumors
Nelson, Blessie Elizabeth , Jankú, Filip , Fu, Siqing , Dumbrava, Ecaterina E. , Hong, David S. , Karp, Daniel D. , Naing, Aung , Tsimberidou, Apostolia M. , Murthy, Ravi , Sheth, Rahul A. , Amaria, Rodabe N. , Carapanceanu, Nicoleta, Singh, Mahendra Pal , Carapanceanu, Valentin, Pezeshki, Abdulmohammad , Leontovich, Alexey A. , Kreider, Brent L. , Tung, David, Varterasian, Mary , Khazaie, Khashayarsha , Piha‐Paul, Sarina A. , Rodon, Jordi , Tsimberidou, Apostolia Maria , Murthy, Ravi , Sheth, Rahul A , Amaria, Rodabe N , Conley, Anthony P , Damodaran, Senthil , Raghav, Kanwal P S , Carapanceanu, Nicoleta , Singh, Mahendra Pal , Carapanceanu, Valentin , Pezeshki, Abdulmohammad , Kreider, Brent , Tung, David , Varterasian, Mary , Khazaie, Khashayarsha , Piha-Paul, Sarina A , Hong, David S , Conley, Anthony P. , Raghav, Kanwal

Mayo Clinic

Clinical Cancer Research | July 11, 2025 | Volume: 31 | Issue: 18 | Pages: 3864-3875

10.1158/1078-0432.ccr-24-3952 | PMID 40643985 Get It

Abstract Purpose: Intratumoral injection of Clostridium novyi-nontoxic (C. novyi-NT), lacking alpha-toxin, germinates and subsequently replicates in the tumor hypoxic regions, causing cell lysis and inflammation. This phase Ib study investigated the safety and synergistic effects of pembrolizumab and C. novyi-NT in advanced solid tumors. Patients and Methods: Patients with injectable solid tumors received one intratumoral C. novyi-NT injection (day 8) across four dose cohorts (3 × 104 to 100 × 104 spores) with pembrolizumab (200 mg intravenously every 3 weeks, day 0–24 months). Sixteen patients were enrolled with a median age of 62.5 years, and the most common tumor types were breast cancer and melanoma. Results: The combination therapy demonstrated a manageable safety profile, with one grade 3 dose-limiting toxicity of abscess formation and the remainder of treatment-related adverse events in ≥10% of patients being grade 1 or 2 injection site reaction (25%), pyrexia (19%), pruritus (13%), leukopenia (13%), and anemia (13%). The maximum tolerated dose was determined to be pembrolizumab intravenously at 200 mg every 3 weeks and a single dose of 100 × 104C.novyi-NT spores intratumorally on day 8. The confirmed overall objective response rate of 25% was observed among four patients with nonkeratinizing undifferentiated nasopharyngeal squamous carcinoma, human papilloma virus–positive squamous cell carcinoma of the base of the tongue, vulvar melanoma, and chordoma. Among these patients, we obtained three partial responses and one complete response. The median duration of the response was 10.93 months, and stable disease was observed in 69% of patients. Conclusions: This study highlights the potential of the C. novyi-NT and pembrolizumab combination as a promising therapeutic strategy for treatment-refractory solid tumors.
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population
Prinzi, Federica Lo , Salani, Francesca , Saborowski, Anna , Antonuzzo, Lorenzo , Rossari, Federico , Satake, Tomoyuki, Peeters, Frederik , Pressiani, Tiziana , Kim, Jin Won , Finkelmeier, Fabian , Chiara, Pircher, Chon, Hong Jae , Braconi, Chiara , Qaisar, Aitzaz, Pastorino, Alessandro , Castet, Florian , Parisi, Alessandro , Perkhofer, Lukas , Adeva, Jorge , Spinelli, Gian Paolo , Rodriquenz, Maria Grazia , Leo, Silvana, Alvim, Cecilia Melo, Polito, M.G. , Giacomo, Emanuela Di , Bartalini, L. , Grelli, Giada, Rosa, Antonio De, Lavacchi, Daniele, Ikeda, Masafumi, Dekervel, Jeroen , Balsano, Rita , Tesini, Giulia , Boccaccino, Alessandra , Himmelsbach, Vera, Vogel, Arndt, Rimassa, Lorenza , Casadei‐Gardini, Andrea, Vogel, Arndt , Casadei‐Gardini, Andrea , Rossari, Federico , Prager, Gerald W , Farinea, Giovanni , Niger, Monica , Rimini, Margherita , Antonuzzo, Lorenzo , Lo Prinzi, Federica , Parisi, Alessandro , Casadei-Gardini, Andrea , Finkelmeier, Fabian , Castet, Florian , Adeva, Jorge , Tesini, Giulia , Rimassa, Lorenza , Casadei-Gardini, Andrea , Saborowski, Anna , Pressiani, Tiziana , Jae Chon, Hong , Salani, Francesca , De Rosa, Antonio , Dekervel, Jeroen , Vogel, Arndt , Camera, Silvia , Lucchetti, Jessica , Abidoye, Oluseyi , Rapposelli, Ilario Giovanni , Gallio, Chiara , Tamberi, Stefano , Giordano, Guido , Chiara, Pircher, Tamburini, Emiliano , Yoo, Changhoon , Diana, Anna , Scartozzi, Mario , Prager, Gerald W. , Avallone, Antonio , Schirripa, Marta , Kim, Il Hwan , Oneda, Ester , Verrico, Monica , Couto, Nuno , Chan, Stephen L. , Personeni, Nicola , Garajova, Ingrid , Roque, Ricardo , Ikeda, Masafumi , Niger, Monica , Tonini, Giuseppe , Kang, Minsu , Landriscina, Matteo , Djaballah, Selma Ahcene , Bekaii‐Saab, Tanios , Fornaro, Lorenzo , Masi, Gianluca , Lonardi, Sara , Rimini, Margherita

Mayo Clinic

International Journal of Cancer | July 11, 2025 | Volume: 157 | Issue: 10 | Pages: 2092-2102

10.1002/ijc.70009 | PMID 40641448 Get It

Abstract In recent years, there has been increasing interest in the possible prognostic impact of concomitant medications in patients with cancer treated with immunotherapy combinations. This real‐world analysis aims to evaluate the impact of concomitant medications on survival outcomes in patients with advanced biliary tract cancer (BTCs) treated with cisplatin, gemcitabine and durvalumab (CGD) therapy. The study cohort included patients with a diagnosis of advanced BTCs who were taking concomitant medications for their comorbidities before the start of CGD. The primary objectives were overall survival (OS) and progression‐free survival (PFS). The initial population consisted of 666 patients, who were retrospectively collected from 41 sites in 12 countries. Data on concomitant medications were available for 493 patients. After a median follow‐up of 8.8 months (95% CI: 7.8–9.8), patients who did not take steroids (prednisone >10 mg/day or equivalent) or nonsteroidal anti‐inflammatory drugs (NSAIDs) and opioids, before the start of CGD, had longer OS and PFS in univariate analysis. The multivariate analysis confirmed longer OS for patients who did not take steroids. Patients who did not take steroids had an OS of 14.8 months (95% CI: 13.1–29.1) versus 5.0 months (95% CI: 2.14–11.32) of patients who took prednisone >10 mg/day or equivalent. No differences were reported in terms of overall response rate (ORR), disease control rate (DCR) ( p = 1.0 and p = .16, respectively), and safety profile between the two groups. Our analysis suggests that patients who did not receive steroids before the start of GCD had longer survival and highlighted the relevance of balancing concomitant medications and chemoimmunotherapy.